Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex

Neurotherapeutics

Volumn 7, Issue 3, 2010, Pages 275-282

  de Vries, Petrus J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Autism; Autism spectrum disorders; Memory; MTOR; Neurocognition; Rapamycin; TSC

Indexed keywords

EVEROLIMUS; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; TEMSIROLIMUS; TUBERIN;

ANGIOMYOLIPOMA; ARTICLE; AUTISM; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; FACE TUMOR; HUMAN; KIDNEY TUMOR; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MISSENSE MUTATION; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; AUTISTIC DISORDER; COGNITION DISORDERS;

AUTISTIC DISORDER; COGNITION DISORDERS; HUMANS; TUBEROUS SCLEROSIS;

EID: 77954888764     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.05.001     Document Type: Article

References (53)

1. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
2. de Vries P.J., Howe C.J. The tuberous sclerosis complex proteins-a GRIPP on cognition and neurodevelopment. Trends Mol Med 2007, 13:319-326.
3. Jones A.C. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997, 6:2155-2161.
4. Dabora S.L. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001, 68:64-80.
5. Roach E.S., Gomez M.R., Northrup H. Tuberous sclerosis consensus conference: revised diagnostic criteria. J Child Neurol 1998, 13:624-628.
6. Ridler K. Neuroanatomical correlates of memory deficits in tuberous sclerosis complex. Cereb Cortex 2007, 17:261-271.
7. Ridler K. Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis. Psychol Med 2001, 31:1437-1446.
8. Franz D.N., de Vries P.J., Crino P.B. Giant cell astrocytomas in tuberous sclerosis complex. Arch Dis Child 2009, 94:75-76.
9. Franz D.N., Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498.
10. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 2010, 51:27-36.
11. Ehninger D., de Vries P.J., Silva A.J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairment in tuberous sclerosis. J Intellect Disabil Res 2009, 53:838-851.
12. Prather P., de Vries P.J. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 2004, 19:666-674.
13. Joinson C. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003, 33:335-344.
14. de Vries P.J., Prather P. The tuberous sclerosis complex. N Engl J Med 2007, 356:92.
15. Bolton P.F., Park R.J., Higgins N.P., Griffiths P.D., Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002, 125:1247-1255.
16. Kelleher R.J., Bear M.F. The autistic neuron: troubled translation?. Cell 2008, 135:401-406.
17. de Vries P.J., Hunt A., Bolton P.F. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2006, 16:16-24.
18. Lewis J.C., Thomas H.V., Murphy K.C., Sampson J.R. Genotype and psychological phenotype in tuberous sclerosis. J Med Genet 2004, 41:203-207.
19. Smalley S.L., Burger F., Smith M. Phenotypic variation of tuberous sclerosis in a single extended kindred. J Med Genet 1994, 31:761-765.
20. de Vries P.J., Gardiner J., Bolton P.F. Neuropsychological attention deficits in tuberous sclerosis complex (TSC). Am J Med Genet Part A 2009, 149A:387-395.
21. McCartney D.L., Bullmore E.T., Suckling J., et al. Lateralised spatial attentional bias and white matter tract connectivity in tuberous sclerosis complex (TSC). J Intell Disabil Res 2009, 53:836.
22. Sahakian B.J., Owen A.M. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J Royal Soc Med 1992, 85:399-402.
23. Kwiatkowski D.J., Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signalling pathways. Hum Mol Genet 2005, 14:R251-R258.
24. Sampson J.R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009, 37:259-264.
25. Jacinto E.R., Loewith A., Schmidt S., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol 2004, 6:1122-1128.
26. Gwinn D.M., Shackelford D.B., Egan D.F., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30:214-226.
27. Serfontein J., Nisbet R.E.R., Howe C.J., de Vries P.J. Evolution of the TSC1/TSC2-TOR signalling pathway. Sci Signal 2010, 3:49.
28. O'Callaghan F.J.K., Harris T., Joinson C., et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004, 89:530-533.
29. Raznahan A., Higgins N.P., Griffiths P.D., Humphrey A., Yates J.R.W., Bolton P.F. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med 2007, 37:1293-1304.
30. Jozwiak S., Domanska-Pakiela D., Kotulska K., et al. New indications for antiepileptic drugs application in infants with tuberous sclerosis complex - prevention of epilepsy. Pharmacol Reports 2009, 61:580-581.
31. Costa-Mattioli M., Sossin W.S., Klann E., Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009, 61:10-26.
32. +/- mice in the absence of cerebral lesions and seizures. Ann Neurol 2007, 62:648-655.
33. +/- mouse model of tuberous sclerosis. Nat Med 2008, 14:843-848.
34. Mozzaffari M., Hoogeveen-Westerveld M., Kwiatkowski D., et al. Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Med Genet 2009, 10:88.
35. Nellist M., Sancak O., Goedbloed M.A., et al. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur J Hum Genet 2005, 13:59-68.
36. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006, 29:349-358.
37. de Vries P.J. Genetics and neuropsychiatric disorders: genome-wide, yet narrow. Nat Med 2009, 15:850-851.
38. Wang L.W., Berry-Kravis E., Hagerman R.J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010, 7:264-274.
39. Kwon C.H., Luikart B.W., Powell C.M., et al. PTEN regulates neuronal arborisation and social interaction in mice. Neuron 2006, 50:377-388.
40. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005, 102:8573-8578.
41. Kenerson H., Dundon T.A., Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005, 57:67-75.
42. Lee L., Sudentas P., Donohue B., et al. Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005, 42:213-227.
43. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
44. Davies D.M., Johnson S.R., Tattersfield A.E., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358:200-203.
45. Hofbauer G.F.L., Marcollo-Pini A., Corsenca A., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. B J Dermatol 2008, 159:473-475.
46. Rauktys A., Lee N., Lee L., Dabora S.L. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 2008, 8:1.
47. Krueger DA, Care MM, Agricola K, et al. Safety and efficacy of RAD001 (everolimus) for the treatment of subependymal giant cell astrocytoma in pediatric and adult patients with TSC. Presented at the TSC International Research Conference, University of Sussex; September 11-13, 2008; Brighton, UK.
48. Zeng L.-H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
49. Meikle L., Pillizzi K., Egnor A., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signalling lead to improved survival and function. J Neurosci 2008, 28:5422-5432.
50. Krueger DA, Holland-Bouley K, Byers AW, et al. Effect of RAD001 (everolimus) on epilepsy and neurocognition in patients with TSC. Presented at the TSC International Research Conference, University of Sussex; September 11-13, 2008; Brighton, UK.
51. Chen X., Garelick M.G., Wang H.B., Athos J., Storm D.R. PI3 kinase signalling is required for retrieval and extinction of contextual memory. Nat Neurosci 2005, 8:925-931.
52. Dash P.K., Orsi S.A., Moore A.N. Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-mammalian target of rapamycin pathway. J Neurosci 2006, 26:8048-8056.
53. de Vries PJ. The Neuroscience of TSC - are we at risk of getting lost between the bench and the bedside? Presented at the International TSC Research Conference: From DNA to Human Therapies; September 23-26, 2009; Chicago.